Adverse events ‐ Withdrawn for medical reasons · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo (moderate certainty).
1 finding from 1 review
Dropout ‐ Studies with low risk of bias · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout ‐ Studies with low risk of bias compared with placebo according to any definition (high certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in severity of depression dichotomous measures ‐ >50% reduction in… compared with placebo according to any definition (low certainty).
1 finding from 1 review
Severity of depression dichotomous measures ‐ "very much" or "much" improved on the Clinical Global Impression Scale · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants may leads to higher severity of depression dichotomous measures ‐ "very much" or "much"… compared with placebo according to any definition (low certainty).
1 finding from 1 review
Severity of depression continuous measures ‐ HDRS total score at the end of the treatment · patients with depression during opioid agonist treatment for opioid dependence
1 finding from 1 review
Adverse events ‐ Withdrawn for medical reasons · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo according to any definition (moderate certainty).
1 finding from 1 review
Dropout · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout compared with placebo (moderate certainty).
1 finding from 1 review
Severity of depression dichotomous measures ‐ "very much" or "much" improved on the Clinical Global Impression Scale · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants may leads to higher severity of depression dichotomous measures ‐ "very much" or "much"… compared with placebo (low certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in severity of depression dichotomous measures ‐ >50% reduction in… compared with placebo (low certainty).
1 finding from 1 review
Quality of sleep · adults with insomnia
1 finding from 1 review
Adverse events · adults with insomnia
1 finding from 1 review
Sleep efficiency · adults with insomnia
1 finding from 1 review
Quality of sleep · adults with insomnia
1 finding from 1 review
Adverse events (at 4, 6 or 12 weeks) · adults with insomnia
Tricyclic antidepressants showed no clear difference in adverse events (at 4, 6 or 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Sleep onset latency ‐ not reported · adults with insomnia
1 finding from 1 review
Sleep efficiency · adults with insomnia
1 finding from 1 review
Total sleep time, next night; · adults with insomnia
1 finding from 1 review
Benzodiazepine discontinuation, end of intervention · adults who withdraw from chronic benzodiazepine use
It is very uncertain whether tricyclic antidepressants changes benzodiazepine discontinuation, end of intervention compared with placebo (very low certainty).
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
Tricyclic antidepressants may leads to higher benzodiazepine discontinuation, longest compared with placebo (low certainty).
1 finding from 1 review
Benzodiazepine withdrawal symptoms, end of intervention · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review